Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.

Launched by EVOTEC NEUROSCIENCES GMBH · Aug 19, 2008

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Smoker of at least 10 cigarettes daily
• • Motivated to quit smoking
• • Reports at least one unsuccessful attempt to quit in the last 2 years
• • In generally good health
• • Provides written informed consent to participate in the sudy
• Exclusion Criteria:
• • Pregnant or nursing females.
• • Women of child-bearing potential must agree to use acceptable contraceptive precautions (contraceptive pill and one barrier method)during the study and for 2-months thereafter
• • History of anaphylaxis
• • History of alcohol or drug abuse
• • History of or current significant medical or psychiatric disorder
• • History or presence of cataract or abnormality identified by slit lamp investigation
• • Use of other MAO inhibitors, pethidine, SSRIs, tricyclic antidepressants,nasal or oral decongestants or cold medicines containing ephedrine, pseudoephedrine or other sympathomimetics.
• • Any medicine contraindicated for use with MAO inhibitors.
• • Have or be a carrier of hepatitis B or c or HIV 1 or 2
• • Use of tobacco products other than cigarettes
• • Use of nicotine replacement therapy in the past month
• • Received an investigational drug in the past 30 days
• • Previous participation in a study with a MAO-B inhibitor